Mouse Study Shows Donor Mitochondria Can Boost Brain and Heart Cells in Friedreich's Model

Stanford's YG8-800 mouse research reveals transplanted mitochondria may improve survival and tissue function in mitochondrial disorder models.

Stanford University researchers used YG8-800 mice—a model of Friedreich's ataxia with human pathogenic FXN mutations—to test mitochondrial transfer. After depleting blood-forming cells and microglia with busulfan and pexidartinib, they transplanted donor marrow. At five months, 82% of brain microglial/myeloid cells were donor-derived, and 22% of recipient bone marrow cells acquired donor mitochondrial signals. Female mice showed improved survival from 53% to 80% with donor marrow, recovered 50% of weight deficit, and demonstrated mitochondrial transfer to neurons and cardiac tissue. The study also noted coordinated upregulation of energy-producing nuclear genes in recipient cells.

The mechanism involves donor mitochondria actively transferring energy production signals across cell types, particularly benefiting affected tissues. While donor-derived macrophages populated the heart, the transfer was more pronounced in diseased mice than healthy controls.

This work suggests a pathway for future therapies targeting mitochondrial disorders by enhancing cellular energy capacity—a critical need for conditions causing progressive neurological and muscular decline. If translated to humans, it could eventually improve access to life-sustaining energy for patients with mitochondrial diseases, which currently lack effective treatments.

Next steps require human trials to confirm safety and efficacy. Current caveats include the mouse model's limitations, speculative transfer mechanisms, no significant survival benefit in males, and incomplete functional recovery in treated mice. The study does not yet address human applications or clinical viability.

Source: Lifespan.io